In Vitro Activity of the Novel Pleuromutilin Lefamulin (BC-3781) and Effect of Efflux Pump Inactivation on Multidrug-Resistant and Extensively Drug-Resistant Neisseria gonorrhoeaeShow others and affiliations
2017 (English)In: Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, E-ISSN 1098-6596, Vol. 61, no 11, article id e01497-17Article in journal (Refereed) Published
Abstract [en]
We evaluated the activity of the novel semisynthetic pleuromutilin lefamulin, inhibiting protein synthesis and growth, and the effect of efflux pump inactivation on clinical gonococcal isolates and reference strains (n = 251), including numerous multidrug-resistant and extensively drug-resistant isolates. Lefamulin showed potent activity against all gonococcal isolates, and no significant cross-resistance to other antimicrobials was identified. Further studies of lefamulin are warranted, including in vitro selection and mechanisms of resistance, pharmacokinetics/pharmacodynamics, optimal dosing, and performance in randomized controlled trials.
Place, publisher, year, edition, pages
American Society for Microbiology , 2017. Vol. 61, no 11, article id e01497-17
Keywords [en]
MtrCDE efflux pump, antimicrobial resistance, gonorrhea, pleuromutilin, treatment
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:oru:diva-62483DOI: 10.1128/AAC.01497-17ISI: 000413558300033PubMedID: 28893785Scopus ID: 2-s2.0-85032498864OAI: oai:DiVA.org:oru-62483DiVA, id: diva2:1160892
Note
Funding agencies:
Örebro County Council Research Committee
Foundation for Medical Research at Örebro University Hospital, Örebro, Sweden
2017-11-282017-11-282024-03-04Bibliographically approved